Smith & Nephew Reports Strong Q3 2025 Growth and Raises Cash Flow Guidance

Smith & Nephew Snats ( (SNN) ) has provided an update.

Smith & Nephew reported a 5.0% underlying revenue growth in the third quarter of 2025, with total revenue reaching $1,501 million. The company highlighted strong performance in its orthopaedics, sports medicine, and advanced wound management divisions, driven by new product launches and strategic initiatives. The company maintained its full-year revenue and profit margin outlook while raising its free cash flow guidance to $750 million, reflecting improved operational efficiency. A $500 million share buyback was completed, showcasing robust cash generation. Smith & Nephew’s strategic focus on innovation and product launches continues to bolster its market position and drive growth.

The most recent analyst rating on (SNN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.

Spark’s Take on SNN Stock

According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.

Smith & Nephew Snats’ strong financial performance and positive earnings call outlook are the primary drivers of its stock score. While technical indicators show mixed momentum, and valuation suggests the stock may be expensive, the company’s robust cash flow and strategic initiatives support a positive outlook. Challenges in emerging markets and potential tariff impacts are notable risks.

To see Spark’s full report on SNN stock, click here.

More about Smith & Nephew Snats

Smith & Nephew is a global medical technology company operating in the orthopaedics, sports medicine, and advanced wound management sectors. The company focuses on developing innovative medical devices and solutions to improve patient outcomes and enhance healthcare delivery.

Average Trading Volume: 664,265

Technical Sentiment Signal: Buy

Current Market Cap: $15.7B

See more insights into SNN stock on TipRanks’ Stock Analysis page.